We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
- Authors
Winston, Alan; Mallon, Patrick W G; Satchell, Claudette; MacRae, Karen; Williams, Kenneth M; Schutz, Malte; Law, Matthew; Cooper, David A; Emery, Sean
- Abstract
Toxicities observed with current combination antiretroviral therapy (CART) warrant a search for novel options, such as class-sparing regimens. Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Vol 44, Issue 11, p1475
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/517507